N-of-One Signs Agreement with Mayo Clinic

By Bio-IT World Staff 

 

May 21, 2014 | Mayo Clinic and N-of-One, have signed an agreement under which N-of-One will provide Mayo Clinic with clinical interpretation information to aid in highly complex molecular diagnostics. In select cases, N-of-One solutions will assist in the identification of biological and clinical knowledge, therapeutic options, and potential clinical trials for patients who undergo next generation cancer sequencing. This will help to translate state-of-the-art knowledge specifically related to individual patients’ tumors into molecularly informed, personalized treatment decisions. 

 

Mayo Clinic will use the clinical interpretation services for Mayo Medical Laboratories, a global reference laboratory operating within Mayo Clinic’s Department of Laboratory Medicine and Pathology, as well as in its Center for Individualized Medicine, which discovers and integrates the latest in genomic, molecular and clinical sciences into personalized care for each Mayo Clinic patient.

 

“The N-of-One team is pleased to work with the talented physicians and geneticists at Mayo Clinic,” said Chris Cournoyer, CEO of N-of-One in a press release. “With the rapidly increasing volume of clinical and scientific data, and hundreds of drugs currently in clinical trials, the task of interpreting molecular test results has become increasingly challenging. We are committed to providing scalable, cost effective genomic clinical decision support that delivers valuable analysis and interpretation of the relevant clinical data to support oncologists in making molecularly informed treatment decisions for their patients.”

 

N-of-One has signed several provider agreements in the past weeks to provide clinical interpretation including ones at Cedars-Sinai Cancer, Dartmouth-Hitchcock Norris Cotton Cancer Center, and OncoDNA in Belgium. In March, the company launched Variant Interpreter, an app available on Illumina’s BaseSpace Apps, letting oncologists, pathologists and researchers request a molecular interpretation of a variant or multiple variants in a tumor using convenient drop-down menus.